Fig. 2From: Proteomics technologies for cancer liquid biopsiesProteomics-based cancer liquid biopsy for translational medicine. A workflow of clinical biomarker discovery divided into three stages (biomarker screening, candidate selection, and large-scale validation and implementation). Untargeted and targeted routes for biomarker exploratory with their analytical scopes are shown. Intensities of the blue color denote their probable significance at individual stagesBack to article page